New stem cell approach targets functional cure for diabetes

Summary

Research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores two significant advancements in stem cell therapy. One area focuses on type 1 diabetes, evaluating immune-engineered, allogeneic insulin-producing cells for their ability to survive and function without chronic immunosuppression, potentially expanding cell replacement therapy. The other highlights a step towards developing a stem cell-based treatment for chronic spinal cord injury (SCI), a condition currently lacking effective restorative therapies.

Why it's important

This research offers potential new avenues for treating conditions with significant unmet medical needs. For type 1 diabetes, the approach could lead to a functional cure by enabling transplanted cells to work effectively without the need for lifelong immunosuppression. For chronic spinal cord injury, it represents a hopeful development in addressing a debilitating condition for which no restorative treatment currently exists.

Key Points

Immune-engineered cell therapy for type 1 diabetes
Stem cell treatment for chronic spinal cord injury
Functional cure for diabetes
ISSCR 2026 Annual Meeting

Involved Entities

International Society for Stem Cell Research (ISSCR)

Sources (3)

New stem cell approach targets functional cure for diabetes